Swiss drug manufacturer PolyPeptide Group is officially exploring strategic options following weeks of speculation regarding potential suitors. The move confirms prior reports that major private equity players were assessing the contract development and manufacturing organization (CDMO). The company’s majority shareholder is coordinating the review, designed to enhance long-term shareholder value, though a definitive transaction is not guaranteed.

Interest from firms like EQT, Advent, and KKR stems from PolyPeptide’s specialized position in peptide-based active pharmaceutical ingredients. The sector is experiencing heightened demand, particularly for therapies addressing chronic conditions such as obesity and diabetes. PolyPeptide is currently executing an internal turnaround strategy focused on scaling capacity and improving operational efficiencies across its global sites in Europe, the US, and India.

Market reaction to the takeover rumors has been immediate and sharp. PolyPeptide’s shares jumped more than 13% following the initial media reports, marking the strongest single-day performance for the stock in over two years. This investor enthusiasm reflects the premium buyers might pay for access to specialized pharma manufacturing capabilities.

Confirmation of the strategic assessment validates the appetite among large financial sponsors for high-growth, specialized biopharma assets. The review process will now determine the ultimate valuation placed on the CDMO’s turnaround trajectory.